KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teladoc Health (TDOC) Shares Outstanding (2016 - 2025)

Teladoc Health (TDOC) has disclosed Shares Outstanding for 13 consecutive years, with $178.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 2.83% to $178.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $178.3 million through Dec 2025, up 2.83% year-over-year, with the annual reading at $178.3 million for FY2025, 2.83% up from the prior year.
  • Shares Outstanding hit $178.3 million in Q4 2025 for Teladoc Health, up from $177.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $178.3 million in Q4 2025 to a low of $154.4 million in Q1 2021.
  • Historically, Shares Outstanding has averaged $166.9 million across 5 years, with a median of $165.2 million in 2023.
  • Biggest five-year swings in Shares Outstanding: skyrocketed 108.44% in 2021 and later increased 1.36% in 2022.
  • Year by year, Shares Outstanding stood at $160.5 million in 2021, then rose by 1.48% to $162.8 million in 2022, then grew by 2.34% to $166.7 million in 2023, then grew by 4.05% to $173.4 million in 2024, then grew by 2.83% to $178.3 million in 2025.
  • Business Quant data shows Shares Outstanding for TDOC at $178.3 million in Q4 2025, $177.3 million in Q3 2025, and $176.6 million in Q2 2025.